POST DOCTORAL BIOINFORMATICIAN
IDENTIFICATION AND VALIDATION OF NEW TARGETS FOR COLORECTAL CANCER
OVERALL OBJECTIVES
The aim of this project is to redefine colorectal cancer (CRC) at the molecular level, by identifying and validating new activated pathways and specific drug targets for defined CRC patient populations. The project will employ the complementary expertise and tools at Astra Zeneca, two academic laboratories (those of Lodewyk Wessels and Rene Bernards at the Netherlands Cancer Institute, Amsterdam) and a leading diagnostics company with an established presence in oncology (Agendia BV, Amsterdam).
PROJECT OUTLINE AND STRATEGY
We will first use computational approaches to perform a ‘pathway’ or ‘module’ level integration of molecular profiling (gene expression and next generation sequencing data) and extensive clinical annotation data from a collection of 400 CRC tumours to identify and prioritise pathways that are deregulated in each CRC sub-disease. Next, we will define for each pathway, targets that are amenable to drug discovery efforts, and that can be validated in cell culture models. To enable target validation, we will develop approaches to identify, based on molecular profiling data, CRC cell lines in the AZ collection that represent each molecular sub-disease. Once these are in place, target validation experiments will be conducted, using established RNAi methodology. Targets whose functions are shown to be essential for cell viability in the appropriate cell line models will then be recommended for new drug discovery projects. These results will be fed back to refine the target section procedure based on the tumor data.
EMPLOYER INFORMATION
The Netherlands Cancer Institute is a dedicated cancer center conducting research in all major areas of cancer, with a strong emphasis on translational research. The Bioinformatics and Statistics group (Wessels lab.) provides leadership on the collection and analysis of data for the research programs of the institute, by developing novel compuational approaches and performing state of the art analyses of a wide array of data types, including laboratory and animal experiments, clinical trials, and epidemiologic studies.
REQUIREMENTS
The ideal candidate is a highly motivated postdoc with a strong background in bioinformatics or computational biology. The vacancy is a research position within the field of bioinformatics/computational biology and the research will be carried out in close collaboration with the involved partners: Bernards lab, Astra Zeneca and Agendia. The ideal candidate has a background in the analysis of high throughput molecular data, computational diagnostics, bioinformatics, computer science, statistics or physics with strong analytical and algorithmic skills.
EMPLOYMENT CONDITIONS
The temporary employment will be for a period of three years. The gross monthly salary for a Postdoc will range from €3140,- to €3.495,- and depends on previous experience. We can help you find housing. The NKI-AVL has been listed in the top 25 of ‘Best Employers’ in 2009 offering a specialized cancer research institute and hospital with good working conditions and an excellent atmosphere.
INTERESTED?
Please contact Dr. Lodewyk Wessels, tel. +31 20 512 7987 or e-mail: l.wessels(a)nki.nl or Dr George Orphanides, Director of Discovery Medicine, tel. +44 1625 232312 or e-mail George.Orphanides(a)astrazeneca.com. When applying please ensure you include a CV, list of publications and the names and addresses of at least two persons that can be approached to obtain further information.
http://bioinformatics.nki.nl
CLOSING DATE
1 May 2011
Dear colleague,
The 2011 International Symposium on Integrative Bioinformatics (IB2011) will
take place on March 21-23, 2011 in Wageningen (the Netherlands). This
seventh meeting on Integrative Bioinformatics will be of interest to
bioinformaticians, computer scientists and all working in, or interested in
the developing area of integrative bioinformatics. There will be
opportunities to present and discuss methods, theoretical approaches, and
their practical applications.
We invite you to register for the conference, and to send in an abstract for
a presentation at the conference. Accepted abstracts will be invited for a
presentation at the conference, and will also be invited to send in a full
manuscript, to be published (after peer reviewing) in the IB2011 Special
Issue of the Journal of Integrative Bioinformatics. The deadline for sending
in an extended abstract is January 15th; submissions should not exceed 4
pages. Authors will be informed of acceptance before February 1st.
There are also opportunities for presenting posters and software
demonstrations at the Symposium. The deadline for sending in abstracts for
posters or a software demo is February 15th, 2011. The best poster will
receive an award sponsored by IMBio e.v.
The conference website is open for registration and abstract submission, and
can be found at www.bioinformatics.nl/ib2011/ and www.imbio.de/ib2011/.
We hope to meet you in March in Wageningen.
On behalf of the organizing committee,
Jack Leunissen
Wageningen UR
IB2011 is organized by Wageningen University, the Leibniz Institute of Plant
Genetics and Crop Plant Research (IPK) Gatersleben, and IMBio e.V.
==
Disclaimer: We have tried our best to remove duplicate e-mail addresses from
our mailing list to reduce the amount of clutter in your mailbox. It may
nevertheless still happen that you receive this mail via different channels.
We apologize if you receive this mail more than once.
On behalf of Simon Lin, chair of CAMDA'11
>
> -------------------
> CAMDA'11 - ISMB Satellite Meeting, Vienna, 15-16 July 2011 --
>
> www.camda.info
>
> Programme announcement & Call for Posters
>
> Dear colleague!
>
> We enthusiastically invite you to attend this year's conference on
>
> Critical Assessment of Massive Data Analysis (CAMDA) .
>
> which will be held 15-16 July 2011 in Vienna, Austria (www.camda.info)
>
>
> The early registration discount for CAMDA/ISMB ends 3 June – book now if you want to join us! This year's exciting line up of keynote speakers includes Terry Speed (WEHI), John Storey (Princeton) and Stefano Volinia (Ferrera). See the full two-day programme for details on papers and events...
>
> CAMDA still accepts poster submissions (abstracts will be published in the conference proceedings).
>
>
> CAMDA was founded in 2000 to provide a forum for the critical assessment of different techniques used in large-scale data analysis in the life-sciences, such as for high-dimensional gene expression profiling. It aims to establish state-of-the-art analysis methods, as well as identify progress and highlight promising directions for future efforts. To this end, CAMDA adopted the approach of a scientific community-wide contest, with everybody analysing the same data sets. Researchers worldwide are invited to take the CAMDA challenge, which has become a prominent fixture (cf. Nature Methods 5, 569). Accepted contributions are presented through talks and posters, and the results and methods of the different analyses are discussed and compared at the conference.
>
> As a special focus this year, we consider the integrated analysis of a particularly rich structured data set that includes gene and miRNA expression, DNA SNPs, copy number variation, and methylation for about 500 matched samples. With the fast ongoing development of novel genome-wide experimental techniques (such as next generation sequencing), an assessment of how we can gain better insight from an integration of heterogeneous large-scale data is particularly topical.
>
> CAMDA was founded by Simon Lin and Kimberly Johnson at Duke University (Nature 411, 885. Nature 424, 610). In 2006 CAMDA became a roving conference, with recent venues including Valencia and Chicago. This year, we will host CAMDA in Austria. For the first time, the conference is run as an official Satellite meeting of ISMB/ECCB, providing further opportunities for interaction with colleagues at the conference.
>
> We can still accept suitable posters for presentations of recent topical work in the dedicated poster session. Poster abstracts are published in the conference proceedings.
>
> Please also distribute this announcement to other colleagues who might be interested.
>
> We look forward to seeing you in Vienna!
>
>
> David Kreil (Boku)
> Joaquin Dopazo (CIPF)
> Simon Lin (Northwestern)
> (chairs)
>
>
> Submission of poster abstracts: open (accepted in order of submission)
> Early registration closes: 3 Jun 2011
> CAMDA 2011 Conference: 15-16 Jul 2011
> ISMB/ECCB 2011 Conference: 17-19 Jul 2011
POSTDOC: COMPUTATIONAL CANCER BIOLOGY
TAILORING TREATMENT FOR COLORECTAL CANCER THROUGH MOLECULAR REDEFINITION OF THE DISEASE VIA INTEGRATED IN SILICO AND IN VITRO ANALYSES
OVERALL OBJECTIVES
The aim of this project is to redefine colorectal cancer (CRC) at the molecular level, in order to identify and validate new activated pathways and specific drug targets for defined CRC patient populations, and to identify molecular markers that can be used to select patients most likely to benefit from drugs active against these targets. The project will employ the complementary expertise and tools at Astra Zeneca, two academic laboratories (those of Lodewyk Wessels and Rene Bernards at the Netherlands Cancer Institute, Amsterdam) and a leading diagnostics company with an established presence in oncology (Agendia BV, Amsterdam)
PROJECT OUTLINE AND STRATEGY
We will first use computational approaches to perform a ‘pathway’ or ‘module’ level integration of molecular profiling and extensive clinical annotation data from a collection of 400 CRC tumors to identify and prioritize pathways that are deregulated in each CRC sub-disease. Next, we will define for each pathway, targets that are amenable to drug discovery efforts, and that can be validated in cell culture models. To enable target validation, we will develop approaches to identify, based on molecular profiling data, CRC cell lines in the AZ collection that represent each molecular sub-disease. Once these are in place, target validation experiments will be conducted, using established RNAi methodology. Targets whose functions are shown to be essential for cell viability in the appropriate cell line models will then be recommended for new drug discovery projects. These results will be fed back to refine the target section procedure based on the tumor data.
EMPLOYER INFORMATION
The Netherlands Cancer Institute is a dedicated cancer center conducting research in all major areas of cancer, with a strong emphasis on translational research. The Bioinformatics and Statistics group (Wessels lab.) provides leadership on the collection and analysis of data for the research programs of the institute, by developing novel compuational approaches and performing state of the art analyses of a wide array of data types, including laboratory and animal experiments, clinical trials, and epidemiologic studies. The candidate will also spend time at Agendia BV, Amsterdam, The Netherlands. Frequent visits to AstraZeneca Oncology, Alderley Park, UK will be undertaken.
REQUIREMENTS
The ideal candidate is a highly motivated postdoc with a strong background in bioinformatics or computational biology. The vacancy is a research position within the field of bioinformatics/computational biology and the research will be carried out in close collaboration with the involved partners: Bernards lab, Astra Zeneca and Agendia. The ideal candidate has a background in the analysis of high throughput molecular data, computational diagnostics, bioinformatics, computer science, statistics or physics with strong analytical and algorithmic skills. Knowledge of biology, particularly signaling pathways and cancer is a strong recommendation.
EMPLOYMENT CONDITIONS
The temporary employment will be for a period of two years. The gross monthly salary for a Postdoc will range from €3140,- to €3.495,- and depends on previous experience. We can help you find housing. The NKI-AVL has been listed in the top 25 of ‘Best Employers’ in 2010 offering a specialized cancer research institute and hospital with good working conditions and an excellent atmosphere.
INTERESTED?
Please contact Dr. Lodewyk Wessels, tel. +31 20 512 7987 or e-mail: l.wessels(a)nki.nl or Dr George Orphanides, Director of Discovery Medicine, tel. +44 1625 232312 or e-mail George.Orphanides(a)astrazeneca.com. When applying please ensure you include a CV, list of publications and the names and addresses of at least two persons that can be approached to obtain further information.
http://bioinformatics.nki.nl
CLOSING DATE
1 September 2011
Dear all,
Applied Maths is currently looking for a BIOINFORMATICS PROGRAMMER for its office in Sint-Martens-Latem (Ghent area).
More information about the job description can be found in attachment.
Please feel free to forward this to any interested party.
Kind regards,
Koen Janssens
____________________________
Koen Janssens
Applications Manager
Applied Maths NV
Keistraat 120 | B-9830 Sint-Martens-Latem | Belgium
Tel: +32 9 22 22 100 | Fax: +32 9 22 22 102
www.applied-maths.com
